Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Press Releases
Hoth Therapeutics, Inc.  
March 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models

avatar profile Olean Times Herald

Olean Times Herald


Local & Social